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Background and purpose: We aimed to determine the burden of comorbidities
at the time of diagnosis of multiple sclerosis (MS), the risk of developing new
comorbidities after diagnosis and the eﬀect of comorbidities on mortality in
patients with MS.
Methods: This study used data from 2526 patients with incident MS and
9980 age-, sex- and physician-matched controls without MS identiﬁed from
the UK Clinical Practice Research Datalink.
Results: Before the MS diagnosis, the adjusted odds ratio for the association
between MS and a Charlson comorbidity index score of 1–2, 3–4 or ≥5 was
131 [95% conﬁdence interval (CI), 1.17–1.47], 1.65 (95% CI, 1.20–2.26) or
3.26 (95% CI, 1.58–6.70), respectively. MS was associated with increased risks
of cardiovascular and neurological/mental diseases. After diagnosis, the
adjusted hazard ratio for the association between MS and an increased risk of
developing comorbidities was 1.13 (95% CI, 1.00–1.29). The risk of developing
any comorbidity in terms of neoplasms, musculoskeletal/connective tissue dis-
eases or neurological/mental diseases was higher in MS. Patients with MS had
a higher mortality risk compared with controls, with a hazard ratio of 2.29
(95% CI, 1.81–2.73) after adjusting for comorbidities. There was a dose eﬀect
of pre-existing comorbidities on mortality.
Conclusions: Patients with MS have an increased risk of developing multiple
comorbidities both before and after diagnosis and pre-existing comorbidities
have an impact on survival.
Introduction
Multiple sclerosis (MS) is a chronic progressive disor-
der characterized by substantial disabilities that may
impair daily activities [1], quality of life and survival
[2]. MS-associated comorbidities at diagnosis may
aﬀect MS management [3] and increase disability
severity [3]. For example, vascular comorbidity was
associated with more rapid disability progression [4]
and epilepsy contributed to a higher mortality risk [5].
Although the awareness of diverse comorbidities in
patients with MS is growing [6,7], temporal changes
in the comorbidity burden and the dose eﬀect of
comorbidity on survival risk have seldom been
addressed.
This study examined the burden of comorbidities in
patients with MS who were listed in the UK Clinical
Practice Research Datalink (CPRD) and were diag-
nosed during 1997–2006. These patients and matched
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controls were followed to compare their subsequent
accrual of comorbidities and all-cause mortality. We
hypothesized, ﬁrst, that patients with MS have higher
risks of comorbidities at diagnosis and of developing
comorbidities following diagnosis and, secondly, that
the extent of comorbidity at MS diagnosis has a dose
eﬀect on survival.
Methods
Data source
The CPRD is a UK primary care database containing
research-standard medical records prospectively col-
lected from 1987 to 2016 (August 2016 version) [8]. A
total of 701 general practitioner (GP) practices con-
tributed in 2007, each caring for an average of 15 963
patients. Our source population comprised all partici-
pants in England who contributed data to the CPRD
between 1 January 1997 and 31 December 2006 and
had valid linkage to secondary care data (Hospital
Episode Statistics). The data were anonymized, elimi-
nating the need for patient consent (approved proto-
col 14-070). CPRD records are well validated for
diagnoses of diseases, including MS [9] and comor-
bidities [10]. This study included two parts: a matched
case–control study to explore the associations of sev-
eral pre-existing comorbidities with incident MS and a
cohort study investigating the incidence of comorbidi-
ties during follow-up of patients with incident MS
compared with subjects without MS.
Definition of incident multiple sclerosis
We used Read codes (Table S1) to identify patients
with MS. The eligibility criteria for patients with inci-
dent MS were (i) no evidence of MS prior to the time
of diagnosis (index date) and (ii) at least a 3-year con-
tinuous CPRD registration prior to the index date [9].
Patients were excluded if they or their GPs were no
longer registered in the CPRD. The deﬁnition of MS
was validated (equivalent to International Classiﬁca-
tion of Diseases-10 (ICD) code 340.0 between 1993
and 2000) and found to have a positive predictive
value of 91.8% [9].
Selection of controls
Each case was randomly matched with up to four
controls without MS from among CPRD participants
who were active during 1997–2006. The controls and
cases were matched by birth year (2 years), sex, reg-
istered GP practice and the ﬁrst year of continuous
registration (2 years) (Fig. 1). The purpose of
matching GP practice and ﬁrst year of continuous reg-
istration was to control for possible confounding due
to registration with a given GP practice. Each of the
matched controls was assigned the index date of their
matched patient with MS and required to have been
registered for at least 3 years before the index date.
Study period
We deﬁned two periods for assessing comorbidity: (i)
the 10 years prior to diagnosis and (ii) the period
from diagnosis to the earliest date of the occurrence
of comorbidities, death, transfer out, last data collec-
tion time for the practice or end of study (30 June
2016), whichever came ﬁrst (Fig. S1).
Comorbidities of interest
We classiﬁed the pre-speciﬁed comorbidities evaluated
into nine categories: neoplasms, cardiovascular dis-
eases, renal diseases, metabolic and endocrine dis-
eases, gastrointestinal and hepatic diseases, chronic
pulmonary diseases, musculoskeletal and connective
tissue diseases, neurological and mental disorders, and
other [11]. To examine the burden of comorbidity in
patients with MS compared with controls, we used
the Charlson comorbidity index (CCI) (Table S2) [12].
The CCI is used to measure individual health status
and comorbidity, and to control for confounding fac-
tors when predicting mortality [13]. We ﬁrst catego-
rized the CCI scores as 0, 1–2, 3–4 or ≥5 and then
dichotomized the values as 0 or ≥1.
All-cause mortality
Mortality and date of death were based on records in
the main CPRD database. The CPRD employs an
algorithm to identify the death dates of the partici-
pants. It was reported previously [14] that the validity
of the recorded date of death in the CPRD has a sen-
sitivity of 0.99 and speciﬁcity of 0.99. The diﬀerence
in the date of death between that in the CPRD and
registration of death was ≤3 months in 98.5% of
deceased patients.
Covariates
Information on demographic factors (age and sex)
and lifestyle factors (body mass index, smoking status
and alcohol consumption) at diagnosis was considered
in this study, as these are potentially modiﬁable fac-
tors aﬀecting MS risk [15–17] and survival [18].
Patients received baseline health checks when they
ﬁrst registered with a GP practice, where the data
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were collected and recorded by nurses using standard
protocols; body mass index (kg/m2) was calculated
from these data.
Statistical analysis
For the matched case–control study, the prevalence of
each comorbidity was calculated using the number of
subjects ever diagnosed with a given comorbidity dur-
ing the 10-year time frame before the index date as
the numerator and the number of patients with inci-
dent MS or matched controls as the denominator. To
estimate the association between MS and each comor-
bidity, we used conditional logistic regression analysis
to calculate odds ratios (ORs), adjusting for lifestyle
factors. Missing data were coded as ‘unknown’. Con-
sidering the variability in follow-up time among the
subjects before the index date, we conducted a sensi-
tivity analysis by changing the period to 3 years.
For the cohort study of incident MS, designed to
investigate the incidence of comorbidities, we followed
the patients from the date of diagnosis to the ﬁrst
recorded diagnosis of a comorbidity and this interval
was deﬁned as the follow-up time. We plotted
Kaplan–Meier curves of the cumulative probability of
the occurrence of a new Charlson comorbidity. In
individuals with no Charlson comorbidity at the index
date, the cumulative probabilities of a new Charlson
comorbidity were estimated at 1, 2, 5 and 10 years.
Only patients without a comorbidity at the index date
were considered in the estimation of hazard ratios
(HRs) for a speciﬁc comorbidity using the Cox pro-
portional hazards model. The HRs were adjusted by
lifestyle factors as well as the matched variables at the
index date.
We plotted Kaplan–Meier curves of the cumulative
probability of the occurrence of all-cause mortality
for patients with MS and controls, adjusting for
covariates and the CCI score at the index date. We
further limited our study to patients with incident MS
to evaluate the relationship between the CCI score at
diagnosis and all-cause mortality using Cox propor-
tional hazards models adjusted for lifestyle factors
and matched variables at the index date.
The Cox proportional hazards models employed in
this study were tested for the assumption of propor-
tionality by examining the log–log plot. The statistical
analyses were conducted using SAS software (version
9.4, Cary, NC, USA).
Results
We identiﬁed 2526 patients with incident MS from
1997 to 2006 with a mean age of 45.0  12.4 years;
71% were female. The median lengths of observation
(interquartile range) before and after the index date
were 12 (7–21) and 10 (5–13) years, respectively. We
followed 9980 controls with similar age and sex distri-
butions and similar observation periods before and
after the index date (Table 1).
Paents with MS in period 1997–2006 (n = 2531)
Connuous registraon for≥ 3-years prior to the index date
Individuals with no evidence of MS in period 1997–2006
(n = 9 335 073)
1. We selected people with connuous registraon for ≥ 3 years prior 
to the index date.
2. MS: controls at 1:4 rao and matched by year of birth, sex, general 
pracce (GP) and year of ﬁrst connuous registraon at the GP’s
pracce
Matched cases (n = 2526) Matched controls (n = 9980)
Figure 1 Flowchart of eligible patients with multiple sclerosis (MS) and controls.
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Retrospective observation
At the index date, 22.7% of patients with MS had at
least one Charlson comorbidity, compared with
16.8% of controls (P < 0.001). Patients with incident
MS tended to have higher CCI scores than those of
the controls (Table 2). Other neurological conditions
were 10-fold more common in patients with MS at
10 years before the MS diagnosis than in matched
controls. Peptic ulcer [OR, 1.60; 95% conﬁdence inter-
val (CI), 1.02–2.50], depression (OR, 1.54; 95% CI,
1.38–1.72) and cardiovascular diseases (OR, 1.18;
95% CI, 1.02–1.37) were also more common in
patients with MS. The sensitivity analysis using a 3-
year time frame before the index date yielded similar
results (Table S3).
In the analysis based on a 1-year time frame, condi-
tions more common in patients with incident MS than
in controls included cerebrovascular diseases (OR,
11.09; 95% CI, 5.74–21.4), neurological and mental
disorders (OR, 3.60; 95% CI, 3.11–4.17), peripheral
vascular diseases (OR, 3.30; 95% CI, 1.05–10.4),
myocardial infarction (OR, 3.07; 95% CI, 1.00–9.43),
hyperlipidaemia (OR, 1.93; 95% CI, 1.16–3.19) and
anaemia (OR, 1.81; 95% CI, 1.25–2.63).
Follow-up data after the index date
Table S4 shows the cumulative probability of any (or a
speciﬁc) comorbidity after MS diagnosis. Among those
with a CCI score of 0 at the index date, the cumulative
probabilities of having a new Charlson comorbidity at 1,
2, 5 and 10 years from the index date were 2.31% (num-
ber of individuals with a new comorbidity/number at
risk at that time point, 57/2479), 4.16% (43/1755),
8.57% (92/1539) and 17.23% (140/1139) in patients with
incident MS, compared with 1.64% (160/9807), 3.10%
(136/7621), 7.83% (404/6881) and 15.78% (543/5250) in
the controls (Fig. S2,P = 0.2333).
The adjusted HR (95% CI) for having a CCI score
≥1 in patients with MS was 1.13 (1.00–1.29). Table 3
shows that patients with MS compared with the con-
trols had a higher risk of developing an incident
comorbidity, including psychosis (adjusted HR, 2.36;
95% CI, 1.34–4.16), depression (adjusted HR, 2.32;
95% CI, 2.04–2.64) and malignancy (adjusted HR,
1.21; 95% CI, 1.00–1.46). Patients with MS had a
lower risk of gout (adjusted HR, 0.59; 95% CI, 0.37–
0.94) compared with controls.
Figure 2 shows the survival curves for patients with
MS and controls. All-cause mortality rates at 5 and
10 years after the index date were 5.11% and 10.27%,
respectively, in patients with incident MS, compared
with 2.09% and 5.08% in controls (log-rank test,
P < 0.0001) (Table S5). The crude and adjusted HRs for
all-cause mortality in patients with MS were 2.38 (95%
CI, 2.02–2.81) and 2.29 (1.81–2.73), respectively
(Table S6).
Next, we evaluated the association between the
baseline CCI score and all-cause mortality in patients
with MS. The 5-year all-cause mortality rates in
patients with MS were 3.67%, 8.22% and 12.45% for
patients with CCI scores of 0, 1 and ≥2 at the index
date, respectively (log-rank test, P < 0.001) (Fig. 3).
After adjusting for lifestyle factors and matched vari-
ables at diagnosis, CCI scores of 1 and ≥2 were asso-
ciated with all-cause mortality (adjusted HR, 1.94;
95% CI, 1.36–2.75; adjusted HR, 3.27; 95% CI, 2.42–
4.42, respectively).
Discussion
At MS diagnosis, the respective prevalences of cere-
brovascular diseases, neurological and mental disor-
ders, peripheral vascular diseases, myocardial
infarction, hyperlipidaemia and anaemia were
Table 1 Baseline characteristics of patients with incident multiple
sclerosis (MS) and controls
Incident MS
(n = 2526)
Controls
(n = 9980)
Adjusted ORs
(95% CI)
Age (years) 45.03  12.37 45.17  12.43
Sex
Men 736 (29.14) 2910 (29.16)
Women 1790 (70.86) 7070 (70.84)
Observation (years)
Prior to
index date
12 (7–21) 12 (7–20)
After index
date
10 (5–13) 10 (6–13)
BMI (kg/m2)
<18.5 983 (38.92) 3452 (34.59) 1.44 (1.07–1.93)*
18.5–24.9 69 (2.73) 169 (1.69) Reference
25.0–29.9 685 (27.12) 2670 (26.75) 0.90 (0.80–1.00)
≥30 469 (18.57) 1871 (18.75) 0.88 (0.77–0.99)
Unknown 320 (12.67) 1818 (18.22) 0.58 (0.50–0.68)
Smoking
Non-smoker 720 (28.50) 2953 (29.59) Reference
Current
smoker
554 (21.93) 1542 (15.45) 1.53 (1.34–1.75)*
Ex-smoker 878 (34.76) 3261 (32.68) 1.09 (0.97–1.24)
Unknown 374 (14.81) 2224 (22.28) 0.62 (0.54–0.72)
Alcohol consumption (units/week)
Never/
ex-drinker
333 (13.18) 1085 (10.87) Reference
Current 1–9 1321 (52.30) 4814 (48.24) 0.90 (0.99–1.08)
Current ≥ 10 268 (10.61) 1030 (10.32) 0.83 (0.68–1.00)*
Unknown 604 (23.91) 3051 (30.57) 0.59 (0.50–0.70)*
BMI, body mass index; CI, conﬁdence interval; OR, odds ratio.
*P < 0.05. Data are given as median (interquartile range), n (%) and
mean  SD.
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signiﬁcantly higher than those in controls. After diag-
nosis, patients with MS were more likely than controls
to develop psychosis, depression and malignancy.
Although the Charlson comorbidity burden was
already higher at the time of MS diagnosis, the risk of
new comorbid conditions in patients after the diagno-
sis of incident MS did not diﬀer from that in controls.
These comorbidities at diagnosis had a dose eﬀect on
the survival of patients with MS. However, MS itself
was associated with increased mortality independent
of comorbidities. Comorbidity is not uncommon in
patients with MS and the accumulation of comorbidi-
ties accompanying MS over time complicates manage-
ment of the disease. Therefore, a good understanding
of comorbidities in MS is needed to improve health
outcomes.
Table 2 Comorbidities present 10 years before the index date
10-year period before the index date
Cases Controls Unadjusted OR Adjusted ORa
Charlson index
0 1952 (77.28) 8303 (83.2) Reference Reference
1–2 501 (19.83) 1518 (15.21) 1.43 (1.27–1.60)* 1.31 (1.17–1.47)*
3–4 59 (2.34) 141 (1.41) 1.82 (1.33–2.49)* 1.65 (1.20–2.26)*
≥5 14 (0.55) 18 (0.18) 3.48 (1.70–7.12)* 3.26 (1.58–6.70)*
Neoplasms 64 (2.53) 226 (2.26) 1.11 (0.83–1.47) 1.08 (0.81–1.45)
Solid malignancy, leukaemia and lymphoma 61 (2.41) 210 (2.1) 1.15 (0.86–1.54) 1.12 (0.84–1.51)
Metastatic solid tumours 4 (0.16) 7 (0.07) 2.00 (0.57–7.01) 1.96 (0.56–6.91)
Cardiovascular diseases 325 (12.87) 1065 (10.67) 1.27 (1.10–1.46)* 1.18 (1.02–1.37)*
Hypertension 222 (8.79) 867 (8.69) 1.00 (0.85–1.18) 0.93 (0.79–1.10)
Cardiac arrhythmias 34 (1.35) 84 (0.84) 1.65 (1.10–2.47)* 1.60 (1.06–2.41)*
Cerebrovascular disease 71 (2.81) 94 (0.94) 3.18 (2.31–4.38)* 2.98 (2.15–4.12)*
Congestive heart failure 13 (0.51) 24 (0.24) 2.01 (1.01–4.01)* 1.96 (0.97–3.95)
Myocardial infarction 23 (0.91) 60 (0.6) 1.55 (0.95–2.54) 1.37 (0.84–2.26)
Peripheral vascular disease 20 (0.79) 47 (0.47) 1.68 (0.99–2.85) 1.48 (0.87–2.53)
Valvular heart disease 9 (0.36) 32 (0.32) 1.13 (0.54–2.37) 1.10 (0.52–2.31)
Genitourinary diseases 18 (0.71) 79 (0.79) 0.89 (0.53–1.49) 0.84 (0.50–1.41)
Urolithiasis 10 (0.4) 48 (0.48) 0.83 (0.42–1.65) 0.77 (0.39–1.53)
Renal diseases 8 (0.32) 32 (0.32) 0.95 (0.44–2.08) 0.93 (0.42–2.03)
Metabolic and endocrine diseases 208 (8.23) 696 (6.97) 1.20 (1.01–1.42)* 1.10 (0.92–1.30)
Uncomplicated diabetes mellitus 67 (2.65) 250 (2.51) 1.04 (0.79–1.37) 0.94 (0.71–1.24)
Diabetes mellitus with complications 20 (0.79) 44 (0.44) 1.77 (1.04–3.01)* 1.56 (0.91–2.67)
Hyperlipidaemia 72 (2.85) 255 (2.56) 1.12 (0.85–1.48) 1.01 (0.76–1.33)
Hypothyroidism 84 (3.33) 260 (2.61) 1.28 (0.99–1.65) 1.20 (0.93–1.56)
Gastrointestinal and hepatic diseases 37 (1.46) 90 (0.9) 1.68 (1.14–2.49)* 1.58 (1.06–2.36)*
Peptic ulcer disease 29 (1.15) 69 (0.69) 1.72 (1.10–2.69)* 1.60 (1.02–2.50)*
Mild liver disease 7 (0.28) 18 (0.18) 1.57 (0.65–3.81) 1.49 (0.61–3.66)
Moderate to severe liver disease 3 (0.12) 7 (0.07) 1.71 (0.44–6.63) 2.08 (0.53–8.19)
Chronic pulmonary diseases 290 (11.48) 970 (9.72) 1.21 (1.05–1.39)* 1.09 (0.95–1.26)
Musculoskeletal and connective tissue diseases 148 (5.86) 509 (5.1) 1.15 (0.94–1.39) 1.06 (0.87–1.29)
Osteoarthritis 63 (2.49) 260 (2.61) 0.94 (0.70–1.25) 0.91 (0.68–1.21)
Rheumatological disease 70 (2.77) 282 (2.83) 0.95 (0.72–1.24) 0.86 (0.65–1.13)
Gout 16 (0.63) 81 (0.81) 0.79 (0.46–1.35) 0.76 (0.44–1.31)
Neurological and mental disorders 882 (34.92) 1783 (17.87) 2.65 (2.39–2.93)* 2.49 (2.24–2.76)*
Dementia 0 (0) 5 (0.05) n.a. n.a.
Other neurological diseases 297 (11.76) 119 (1.19) 11.3 (9.00–14.2)* 10.72 (8.52–13.5)*
Psychosis 14 (0.55) 31 (0.31) 1.81 (0.96–3.40) 1.70 (0.90–3.22)
Depression 616 (24.39) 1683 (16.86) 1.67 (1.49–1.86)* 1.54 (1.38–1.72)*
Other comorbidities 252 (9.98) 871 (8.73) 1.16 (1.00–1.35)* 1.10 (0.94–1.28)
Anaemia 210 (8.31) 671 (6.72) 1.27 (1.07–1.50)* 1.19 (1.01–1.41)*
Psoriasis 48 (1.9) 211 (2.11) 0.90 (0.66–1.24) 0.88 (0.64–1.21)
HIV infection 0 (0) 2 (0.02) n.a. n.a.
Charlson index includes myocardial infarction, congestive heart failure, peripheral vascular disease, cerebrovascular disease, dementia, chronic
pulmonary disease, rheumatologic disease, peptic ulcer disease, mild liver disease, moderate/severe liver disease, diabetes mellitus (DM), DM
with chronic complications, renal diseases, any malignancy (including leukaemia and lymphoma), metastatic solid tumour and human immun-
odeﬁciency virus (HIV) infection. n.a., not applicable; OR, odds ratio. aAdjusted for body mass index class, smoking status and alcohol con-
sumption. *P < 0.05. Data are given as median (interquartile range) and n (%).
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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Several systematic reviews conﬁrmed that comor-
bidities are common in patients with MS [6,19,20]. In
general, however, previous studies did not evaluate
the clinical course of MS relative to diagnosis. Consis-
tent with previous research, this study found that car-
diovascular diseases including cardiac arrhythmia,
ischemic heart disease and congestive heart failure [7],
mental disorders (particularly depression) [6] and
probably certain types of cancer [7] seem more com-
mon in the MS population than in controls.
The relationships between MS and comorbidities
are complex [21] and can be broadly classiﬁed as
direct causal relationships, associated risk factors or
heterogeneous eﬀects [22]. For example, mental health
problems in patients with MS are common [6].
Although the pathophysiology is not fully understood,
both MS lesions and microstructural white matter
changes may lead to mental health manifestations
such as depression [23]. Other factors such as genetic
and psychosocial factors may also be involved in the
link between depression and MS [24]. Our results sup-
port associations between MS and psychiatric ill-
nesses.
Associated comorbidities have implications for clini-
cal management of MS [3]. First, the existence of
comorbidities may complicate MS management. For
Table 3 Risk of incident comorbidity after the diagnosis of multiple sclerosis (MS) compared with controls without MS
MS cases Controls without MS Unadjusted HRs Adjusted HRsa
Charlson index ≥ 1 1952 (20.34) 8303 (18.85) 1.19 (1.05–1.34)a 1.13 (1.00–1.29)a
Any increase in Charlson index 2526 (15.72) 9980 (15.68) 1.08 (0.96–1.22) 1.05 (0.92–1.19)
Neoplasms 2462 (7.27) 9754 (6.55) 1.24 (1.03–1.50)a 1.22 (1.01–1.48)a
Solid malignancy, leukaemia and lymphoma 2464 (7.22) 9763 (6.59) 1.23 (1.02–1.48)a 1.21 (1.00–1.46)a
Metastatic solid tumours 2522 (0.59) 9973 (0.74) 0.79 (0.44–1.41) 0.73 (0.40–1.32)
Cardiovascular diseases 2201 (15.77) 8915 (17.52) 1.00 (0.87–1.13) 0.97 (0.84–1.11)
Hypertension 2304 (11.46) 9113 (14.38) 0.91 (0.78–1.05) 0.89 (0.76–1.03)
Cardiac arrhythmias 2492 (1.97) 9896 (2.33) 0.98 (0.70–1.36) 0.97 (0.69–1.36)
Cerebrovascular disease 2455 (3.01) 9886 (2.83) 1.12 (0.85–1.47) 1.08 (0.81–1.44)
Congestive heart failure 2513 (0.76) 9956 (0.92) 1.01 (0.61–1.67) 1.00 (0.61–1.65)
Myocardial infarction 2503 (1.28) 9920 (1.32) 1.09 (0.72–1.65) 1.04 (0.67–1.61)
Peripheral vascular disease 2506 (1.00) 9933 (0.94) 1.32 (0.82–2.13) 1.42 (0.84–2.39)
Valvular heart disease 2517 (0.87) 9948 (0.71) 1.41 (0.87–2.28) 1.32 (0.79–2.21)
Genitourinary diseases 2508 (1.59) 9901 (1.55) 1.08 (0.77–1.52) 1.03 (0.72–1.47)
Urolithiasis 2516 (0.64) 9932 (0.43) 1.47 (0.83–2.63) 1.52 (0.81–2.85)
Renal diseases 2518 (0.95) 9948 (1.14) 0.90 (0.58–1.38) 0.83 (0.53–1.31)
Metabolic and endocrine diseases 2318 (11.69) 9284 (11.75) 1.08 (0.93–1.26) 1.08 (0.93–1.27)
Uncomplicated diabetes mellitus 2459 (4.51) 9730 (4.44) 1.10 (0.88–1.38) 1.08 (0.84–1.40)
Diabetes mellitus with complications 2506 (4.27) 9936 (4.58) 1.07 (0.84–1.37) 1.03 (0.78–1.35)
Hyperlipidaemia 2454 (5.26) 9725 (5.68) 1.03 (0.82–1.29) 1.00 (0.80–1.26)
Hypothyroidism 2442 (3.97) 9720 (3.72) 1.07 (0.85–1.35) 1.03 (0.81–1.30)
Gastrointestinal and hepatic diseases 2489 (1.69) 9890 (1.32) 1.43 (0.99–2.07) 1.39 (0.94–2.05)
Peptic ulcer disease 2497 (0.76) 9911 (0.61) 1.47 (0.85–2.54) 1.45 (0.82–2.55)
Mild liver disease 2519 (0.87) 9962 (0.7) 1.28 (0.76–2.17) 1.11 (0.61–2.00)
Moderate to severe liver disease 2523 (0.08) 9973 (0.14) 0.62 (0.14–2.85) 1.08 (0.27–4.29)
Chronic pulmonary diseases 2236 (5.37) 9010 (6.57) 0.86 (0.70–1.06) 0.83 (0.67–1.03)
Musculoskeletal and connective tissue diseases 2378 (10.26) 9471 (8.72) 1.24 (1.07–1.45)a 1.20 (1.02–1.40)a
Osteoarthritis 2463 (4.51) 9720 (5.47) 0.90 (0.74–1.10) 0.92 (0.75–1.14)
Rheumatological disease 2456 (3.46) 9698 (4.10) 0.89 (0.70–1.15) 0.86 (0.66–1.11)
Gout 2510 (1.00) 9899 (1.72) 0.64 (0.42–0.97) 0.59 (0.37–0.94)
Neurological and mental disorders 1644 (30.54) 8197 (15.08) 2.61 (2.28–2.99)a 2.50 (2.17–2.88)a
Dementia 2526 (0.51) 9975 (0.51) 1.12 (0.56–2.25) 1.28 (0.66–2.49)
Other neurological diseases 2229 (5.29) 9861 (1.53) 4.33 (3.21–5.83)a 4.49 (3.28–6.13)a
Psychosis 2512 (1.00) 9949 (0.42) 2.24 (1.32–3.80)a 2.36 (1.34–4.16)a
Depression 1910 (26.54) 8297 (13.49) 2.43 (2.14–2.76)a 2.32 (2.04–2.64)a
Other comorbidities 2274 (8.62) 9109 (8.54) 1.02 (0.86–1.20) 0.99 (0.83–1.18)
Anaemia 2322 (7.49) 9331 (7.35) 1.01 (0.85–1.21) 0.99 (0.81–1.19)
Psoriasis 2478 (1.74) 9769 (1.73) 1.13 (0.79–1.62) 1.18 (0.80–1.73)
HIV infection 2526 (0.00) 9978 (0.00) n.a. n.a.
Figures show the number in the at-risk population (percentage of the at-risk population who developed incident comorbidity) and hazard
ratios (HRs) (95% conﬁdence interval). aAdjusted for body mass index class, smoking status and alcohol consumption. bP < 0.05. HIV, human
immunodeﬁciency virus; n.a., not applicable. Data are given as median (interquartile range) and n (%).
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example, ﬁngolimod, a medication commonly used to
treat MS, is contraindicated in patients with recent
cardiovascular problems [25]. Secondly, an assessment
of comorbidities at diagnosis and during follow-up
seems warranted, as one-third of the patients with MS
in this study developed a comorbidity within 5 years
of diagnosis. Thirdly, a comorbidity index can be used
to estimate prognosis by considering the overall
comorbidity burden and its eﬀects on mortality risk in
MS.
Three main limitations of this study need to be dis-
cussed. First, misclassiﬁcation bias may exist for MS
and comorbidities, given that physician diagnoses
were used as case deﬁnitions. However, the validity of
the diagnoses of MS and most comorbidities in the
CPRD has been validated [9,10]. With identical case
deﬁnitions for all patients, the potential for diﬀerential
misclassiﬁcation should be minimized. Secondly, the
possibility of ascertainment bias between patients with
incident MS and controls cannot be excluded entirely.
The nature of healthcare utilization may lead to a
higher probability of identifying comorbidities in regu-
lar users of healthcare services. Thirdly, some poten-
tial confounders such as ethnicity, education, annual
household income and treatment methods were not
considered.
Conclusions
Patients with MS have increased risks of developing
multiple comorbidities both before and after diagnosis
and pre-existing comorbidities have a dose eﬀect on
survival.
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Figure S1. Observation of comorbidities in a patient
with incident multiple sclerosis.
Figure S2. The cumulative probabilities of developing
a new Charlson comorbidity in patients with multiple
sclerosis (MS) (red) and matched controls without MS
(blue) who had a Charlson comorbidity index score of
0 at the index date.
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